Tanespimycin (17-AAG)

For research use only. Not for use in humans.

目录号：S1141 别名： CP127374,NSC-330507, KOS 953 中文名称：坦螺旋霉素

Tanespimycin (17-AAG) Chemical Structure

CAS No. 75747-14-7

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) 是一种有效的HSP90抑制剂，无细胞试验中IC50为5 nM，作用于来自肿瘤细胞的HSP90比作用于来自正常细胞HSP90结合亲和力高100倍。Tanespimycin (17-AAG)可诱导细胞凋亡、坏死、自噬和线粒体自噬。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2350.91	现货
5mg	RMB 795.18	现货
25mg	RMB 2432.97	现货
100mg	RMB 6527.43	现货
200mg	RMB 10950.03	现货
大包装

大剂量询单

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Tanespimycin (17-AAG)发表文献81篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Cell Rep, 2020, 33(7):108397

PubMed: 33207204 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(4)

PubMed: 32272809 ( click the link to review the publication )

Mol Cell Biol, 2020,

PubMed: 32868290 ( click the link to review the publication )

Mol Cell Biol, 2020, MCB.00473-20

PubMed: 33139492 ( click the link to review the publication )

Phytomedicine, 2020,

PubMed: 32896707 ( click the link to review the publication )

Drug Des Devel Ther, 2020, 14:4605-4612

PubMed: 33149557 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Front Cell Dev Biol, 2019, 7:204

PubMed: 31608279 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )
Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(4)e00375-18

PubMed: 30455251 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27397

PubMed: 30378153 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

Eur J Med Chem, 2018, 158:548-558

PubMed: 30243156 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28619760 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4465-4480

PubMed: 28973376 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )
Oncotarget, 2017, 8(62):105372-105382

PubMed: 29285257 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2089

PubMed: 26866270 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(9):2738-47

PubMed: 26077647 ( click the link to review the publication )

Cancer Biol Ther, 2015,

PubMed: 25692408 ( click the link to review the publication )

Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )
Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

产品安全说明书

HSP (HSP90)抑制剂选择性比较

生物活性

产品描述

特性

17-AAG对正常细胞的毒性很小。

靶点

HSP90 ^[1]
(Cell-free assay)

5 nM

体外研究

17-AAG是格尔德霉素类似物, 但是与过量表达HER-2的癌细胞 (BT474, N87, SKOV3 和SKBR3)或BT474乳腺细胞衍生的Hsp90亲和力高100多倍，IC50为5-6 nM, 而作用于正常人类原代细胞时，IC50为400-943 nM, 因为肿瘤Hsp90 处于多伴复合体状态，具有高ATP酶活性，而正常细胞Hsp90 处于潜在未结合状态, 且直接与那些细胞中17-AAG毒性相关。^[1]17-AAG 引起HER2, HER3, Akt，突变和野生型雄激素受体(AR)降解，导致前列腺细胞如LNCaP, LAPC-4, DU-145,和PC-3中RB依赖的 G1 期生长停顿，IC50为25-45 nM。^[2]除了诱导改变野生型BCR-ABL的Ba/F3细胞凋亡, IC50为5.2 μM, 17-AAG还通过诱导野生型和突变型 BCR-ABL蛋白降解，而诱导改变抗 Imatinib Mesylate的 T315I和 E255K BCR-ABL突变型细胞生长，IC50分别为2.3 μM 和 1.0 μM。^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	M2TTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf2NW9DUUN3ME2wMlAxODNyMzFOwG0>	NIjSNZlUSU6JRWK=
IST-MEL1	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjwUHdKSzVyPUCuNFAxPDB5IN88US=>	M13xSnNCVkeHUh?=
NCI-SNU-1	NHSxeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\YcGlEPTB;MD6wNFIxPyEQvF2=	MorqV2FPT0WU
FADU	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMECyNFkh\|ryP	M2izT3NCVkeHUh?=
C32	M4\xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXKTWM2OD1yLkCwN\|A1KM7:TR?=	Moe5V2FPT0WU
D-566MG	NH;Qb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fuPGlEPTB;MD6wNFM6KM7:TR?=	NWfVelFPW0GQR1XS
LXF-289	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3QeJR1UUN3ME2wMlAxPDF7IN88US=>	M3LFS3NCVkeHUh?=
HGC-27	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[wOWlEPTB;MD6wNFUyKM7:TR?=	NEnNXmlUSU6JRWK=
RPMI-7951	NWnPcZpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvIPGJKSzVyPUCuNFA4OTdizszN	MXPTRW5ITVJ?
HSC-3	M4niRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;CS2lEPTB;MD6wNFkzQSEQvF2=	MoTMV2FPT0WU
MIA-PaCa-2	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEGwNFkh\|ryP	NFvMTINUSU6JRWK=
KS-1	M37uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3mUpdSUUN3ME2wMlAyOzV3IN88US=>	NV2xRVFIW0GQR1XS
CAL-51	NWi1d2piT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHKRnZKSzVyPUCuNFE1ODVizszN	MWfTRW5ITVJ?
MDA-MB-361	M{j6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDWTWM2OD1yLkCxOFk2KM7:TR?=	MYDTRW5ITVJ?
TI-73	M3f3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\sTWM2OD1yLkCxO\|k3KM7:TR?=	MVTTRW5ITVJ?
AGS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEG5N\|gh\|ryP	MlvVV2FPT0WU
NCI-H460	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXroVoo4UUN3ME2wMlAyQTd2IN88US=>	M{jnS3NCVkeHUh?=
A204	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvBdm1KSzVyPUCuNFIzPDlizszN	NYHZRXpDW0GQR1XS
CHL-1	M4foc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\WTmlEPTB;MD6wNlI2OSEQvF2=	MVrTRW5ITVJ?
DU-4475	NIXQO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPITWM2OD1yLkCyNlYyKM7:TR?=	M1vRNXNCVkeHUh?=
CGTH-W-1	MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vrNGlEPTB;MD6wNlM1QSEQvF2=	NUjCRVhXW0GQR1XS
HCC2218	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;oTWM2OD1yLkCyOFk1KM7:TR?=	M2jHbnNCVkeHUh?=
A2780	NVPicZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjoeXk1UUN3ME2wMlAzPTNzIN88US=>	MkHCV2FPT0WU
NCI-H720	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVm1WYhxUUN3ME2wMlAzPTR4IN88US=>	NUPBSoRiW0GQR1XS
NCI-N87	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXCTFhKSzVyPUCuNFI2QTNizszN	M33VZ3NCVkeHUh?=
CHP-212	NV;zWFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHNN\|hKSzVyPUCuNFI3OjhizszN	MkDDV2FPT0WU
NCI-H23	M{KxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMEK2OlUh\|ryP	NVy0e3JSW0GQR1XS
D-263MG	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEK3PFYh\|ryP	MkfEV2FPT0WU
ME-180	NFezNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHhenZKSzVyPUCuNFI5QTFizszN	NFXpOmRUSU6JRWK=
SW982	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEK5PVkh\|ryP	M3HvWXNCVkeHUh?=
OE19	NXLBZnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEOwO\|ch\|ryP	MWnTRW5ITVJ?
SK-LU-1	M3TUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13kfmlEPTB;MD6wN\|A5OiEQvF2=	NIX0WWZUSU6JRWK=
H4	Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvRTWM2OD1yLkCzNFkh\|ryP	MVPTRW5ITVJ?
HT-144	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nyTGlEPTB;MD6wN\|A6OyEQvF2=	NYnkUGxnW0GQR1XS
SK-UT-1	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojsTWM2OD1yLkCzNVc5KM7:TR?=	MleyV2FPT0WU
D-336MG	M1q1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4W5b2lEPTB;MD6wN\|MxQSEQvF2=	M4Szb3NCVkeHUh?=
MDA-MB-175-VII	M3\1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLDTWM2OD1yLkCzN\|U1KM7:TR?=	M4[2eXNCVkeHUh?=
GAMG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEO0N\|Uh\|ryP	M1[xPHNCVkeHUh?=
CP50-MEL-B	M4O0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX23ZVlDUUN3ME2wMlA{PDVizszN	MXzTRW5ITVJ?
OVCAR-5	NGHSdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDR[VVKSzVyPUCuNFM1QCEQvF2=	NEjsfYRUSU6JRWK=
SK-MES-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD3eoJpUUN3ME2wMlA{PjB4IN88US=>	MWfTRW5ITVJ?
VM-CUB-1	NUj6RnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\MRoFKSzVyPUCuNFM3PTdizszN	MVjTRW5ITVJ?
WM-115	NFPkOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTmTWM2OD1yLkCzO\|YzKM7:TR?=	NX3nR4V4W0GQR1XS
DSH1	M3XxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X5SGlEPTB;MD6wN\|gxPyEQvF2=	Ml3nV2FPT0WU
Becker	NV;kSXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7h[WtKSzVyPUCuNFM5QDVizszN	M1rLN3NCVkeHUh?=
SW962	NFHjTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHjTWM2OD1yLkCzPVQ2KM7:TR?=	MX3TRW5ITVJ?
TYK-nu	NYDPW4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEO5PFUh\|ryP	NX3PVGxIW0GQR1XS
HO-1-N-1	NX7q[YxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OxdmlEPTB;MD6wOFAzOSEQvF2=	M17oVXNCVkeHUh?=
T98G	NW\1R5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMESxNFMh\|ryP	NHKz[XVUSU6JRWK=
ACN	NVzs[\|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDHTWM2OD1yLkC0NVYzKM7:TR?=	M1PnOXNCVkeHUh?=
SW780	NH;CfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DRemlEPTB;MD6wOFIxOyEQvF2=	NYnEc4JPW0GQR1XS
Detroit562	NF;zZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor4TWM2OD1yLkC0NlM6KM7:TR?=	NUTUfY96W0GQR1XS
BB49-HNC	NVeyfFNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvJ[XRyUUN3ME2wMlA1OjR\|IN88US=>	M{L1UHNCVkeHUh?=
HN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWixV5p3UUN3ME2wMlA1Ojd{IN88US=>	NIfpbGtUSU6JRWK=
H9	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jhNWlEPTB;MD6wOFM4OSEQvF2=	NUjNUW1MW0GQR1XS
VA-ES-BJ	NX\rVJliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLJbnVrUUN3ME2wMlA1PDR5IN88US=>	M3LxTnNCVkeHUh?=
MEL-JUSO	NUXXcotpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMES0O\|Uh\|ryP	NEDEUVRUSU6JRWK=
BT-474	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMES1JO69VQ>?	NVvTXm1QW0GQR1XS
CaR-1	M2rZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fQVmlEPTB;MD6wOFU1QSEQvF2=	Ml\TV2FPT0WU
PSN1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HwOWlEPTB;MD6wOFYxOyEQvF2=	MUHTRW5ITVJ?
KYSE-510	M1;vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPiTWM2OD1yLkC0OlQ6KM7:TR?=	NHXDeoNUSU6JRWK=
KP-4	M4HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrubZdKSzVyPUCuNFQ4PTNizszN	MkjLV2FPT0WU
KYSE-410	NH;kOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHPTWM2OD1yLkC0O\|czKM7:TR?=	MXzTRW5ITVJ?
G-402	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMES3PFkh\|ryP	NGjTXWxUSU6JRWK=
DOK	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMES5NFIh\|ryP	Ml[4V2FPT0WU
COR-L88	MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknHTWM2OD1yLkC0PVEzKM7:TR?=	NX7TSXhkW0GQR1XS
SKG-IIIa	NVXIT3prT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi5SWl[UUN3ME2wMlA1QTh4IN88US=>	MXLTRW5ITVJ?
AN3-CA	NUTXdlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInhNmNKSzVyPUCuNFUh\|ryP	NV2yWohkW0GQR1XS
SW48	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j0dGlEPTB;MD6wOVA{QSEQvF2=	MUPTRW5ITVJ?
YKG-1	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NES0R2pKSzVyPUCuNFUxPzFizszN	MVnTRW5ITVJ?
KYSE-150	NIXkOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O1ZmlEPTB;MD6wOVI{PSEQvF2=	NGTQV41USU6JRWK=
HuO-3N1	NYXtZnBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XMb2lEPTB;MD6wOVI{PyEQvF2=	NWHadFVDW0GQR1XS
LB1047-RCC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLUNHpKSzVyPUCuNFUzQTZizszN	MWfTRW5ITVJ?
NCI-H2030	M2\1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFOxbHdKSzVyPUCuNFU1OTRizszN	M1TLUXNCVkeHUh?=
YH-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\W[2lEPTB;MD6wOVczOiEQvF2=	NI\IRoNUSU6JRWK=
5637	NHLjNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPHO2VKSzVyPUCuNFU4PCEQvF2=	MXrTRW5ITVJ?
LOXIMVI	M3G3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO2TJJlUUN3ME2wMlA2QDd{IN88US=>	MYnTRW5ITVJ?
GT3TKB	NHPxU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[4V4xKSzVyPUCuNFU6PDJizszN	MV7TRW5ITVJ?
TCCSUP	NFjEZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEW5OlQh\|ryP	MUTTRW5ITVJ?
EPLC-272H	M3ntZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\VWGlEPTB;MD6wOlIxPSEQvF2=	MnThV2FPT0WU
LU-99A	NV\SRnR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPnSnRKSzVyPUCuNFYzOzdizszN	NWTy[2JpW0GQR1XS
NCI-H1755	NVf1PVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PC[WlEPTB;MD6wOlM1OSEQvF2=	MWHTRW5ITVJ?
KM12	M4rUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwME[zOFgh\|ryP	NV7GTnUyW0GQR1XS
SF295	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvx[49kUUN3ME2wMlA3PDV{IN88US=>	NXLnPYI5W0GQR1XS
MZ2-MEL	NFPVUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwME[1OVMh\|ryP	M2LrS3NCVkeHUh?=
HEC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LFV2lEPTB;MD6wOlU5QCEQvF2=	M{jr[nNCVkeHUh?=
SW684	NF7lbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13SSmlEPTB;MD6wOlU6OSEQvF2=	NUDVTnNLW0GQR1XS
SF539	NYDuXZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwME[2PFEh\|ryP	Mlj1V2FPT0WU
GMS-10	NXnnR4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwME[2PVkh\|ryP	NHy5WHhUSU6JRWK=
MV-4-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PkdGlEPTB;MD6wOlgxOyEQvF2=	M3HRTXNCVkeHUh?=
HT-29	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnYeVhKSzVyPUCuNFY6OTlizszN	NFO1dVZUSU6JRWK=
23132-87	M3rq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHlTWM2OD1yLkC2PVUh\|ryP	NVLubFhbW0GQR1XS
SW620	M4m3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEewNlYh\|ryP	NXmwcGxqW0GQR1XS
HCC1806	NVzlUW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrwTWM2OD1yLkC3NVMyKM7:TR?=	MnXDV2FPT0WU
Hs-578-T	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\z[mlEPTB;MD6wO\|IxQCEQvF2=	M3fQ[XNCVkeHUh?=
A2058	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzkbWJ[UUN3ME2wMlA4OjJ6IN88US=>	M3\McHNCVkeHUh?=
MEL-HO	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnSxTWM2OD1yLkC3NlU2KM7:TR?=	M13udXNCVkeHUh?=
HCC2998	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEezOFch\|ryP	MlzQV2FPT0WU
HuO9	NVfYVIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DBT2lEPTB;MD6wO\|U5QSEQvF2=	MUDTRW5ITVJ?
CAL-39	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3pTWM2OD1yLkC3O\|Y3KM7:TR?=	NWmzZYg4W0GQR1XS
M14	M1flUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r4OGlEPTB;MD6wO\|kyOyEQvF2=	MnTDV2FPT0WU
BFTC-909	M{TEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLaTWM2OD1yLkC3PVY6KM7:TR?=	NWjtNYFqW0GQR1XS
TE-11	NFHDfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPUN25[UUN3ME2wMlA4QTl4IN88US=>	NX31[FB{W0GQR1XS
TGBC1TKB	M2LENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMEiwOFMh\|ryP	NXPkN4VXW0GQR1XS
L-363	NETyfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\TW3JKSzVyPUCuNFgzODZizszN	NWnWZYNSW0GQR1XS
A431	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfLOlNQUUN3ME2wMlA5OjFizszN	NH\zcohUSU6JRWK=
MKN45	NE\wcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfqN3BKSzVyPUCuNFgzOTlizszN	NUjPVlVHW0GQR1XS
HT-1080	NFHCZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEi0N\|kh\|ryP	M{G4NHNCVkeHUh?=
OVCAR-8	M4O5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XXTWlEPTB;MD6wPFYzOiEQvF2=	MWLTRW5ITVJ?
LCLC-97TM1	NWjV[ZdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2D6S2lEPTB;MD6wPFczQCEQvF2=	MWLTRW5ITVJ?
M059J	M2nHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PzSWlEPTB;MD6wPVAzPyEQvF2=	MWDTRW5ITVJ?
SK-MEL-2	NHr4SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMEmwOkDPxE1?	M2LQ[HNCVkeHUh?=
TE-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rOd2lEPTB;MD6wPVIxPCEQvF2=	MmTSV2FPT0WU
KYSE-180	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEmyOlIh\|ryP	MVHTRW5ITVJ?
D-247MG	M4L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMEm0OVUh\|ryP	NUXjT216W0GQR1XS
8-MG-BA	NUS2ZlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;pTnoxUUN3ME2wMlA6PDd{IN88US=>	M1y3R3NCVkeHUh?=
NCI-H1792	NUe1boV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzhV2dKSzVyPUCuNFk3OThizszN	MW\TRW5ITVJ?
MCF7	NWHhSFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[0UZZOUUN3ME2wMlA6Pjd5IN88US=>	NXvCcmwxW0GQR1XS
NCI-H2122	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTn[FZ4UUN3ME2wMlA6PzR3IN88US=>	NIXn[mRUSU6JRWK=
EFO-27	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHXTWM2OD1yLkC5PVk4KM7:TR?=	NGLXWVNUSU6JRWK=
LB2241-RCC	M{j6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fQR2lEPTB;MD6xNFA2PCEQvF2=	NYPMRo9tW0GQR1XS
SN12C	NXrvVXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMUCxNFch\|ryP	M{XkUnNCVkeHUh?=
A498	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfyTWM2OD1yLkGwNVgh\|ryP	M3jMdnNCVkeHUh?=
PANC-03-27	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvzWpFkUUN3ME2wMlExOjh4IN88US=>	Mnn1V2FPT0WU
NCI-H1581	NULKRWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMUCyPUDPxE1?	MoOzV2FPT0WU
U-87-MG	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMUCzNFch\|ryP	NEHXeHdUSU6JRWK=
G-401	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrRTWM2OD1yLkGwN\|U{KM7:TR?=	NV3UUGxSW0GQR1XS
SiHa	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMUC0PFYh\|ryP	NYTQR2RuW0GQR1XS
U251	NV24[ohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;XTWM2OD1yLkGwOVI2KM7:TR?=	MoeyV2FPT0WU
MMAC-SF	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLaUHpKSzVyPUCuNVA2OzFizszN	MmHIV2FPT0WU
BB65-RCC	NFTxcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfYTWM2OD1yLkGwOVU1KM7:TR?=	NHi2WJZUSU6JRWK=
NKM-1	NInsVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMUC2OlYh\|ryP	NIfW[3lUSU6JRWK=
HD-MY-Z	NYDQdYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4raNWlEPTB;MD6xNFg4OyEQvF2=	MkLCV2FPT0WU
TGBC11TKB	NHuyelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMUC5NFMh\|ryP	M1f0cXNCVkeHUh?=
COLO-679	NFP1TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XLcWlEPTB;MD6xNVIyOSEQvF2=	NEXIcphUSU6JRWK=
TE-8	M1zMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TwU2lEPTB;MD6xNVI3PCEQvF2=	M1rOUXNCVkeHUh?=
SK-MEL-28	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;oTWM2OD1yLkGxN\|IyKM7:TR?=	NGe0c4pUSU6JRWK=
SH-4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrsNZBKSzVyPUCuNVE{PTZizszN	MkLpV2FPT0WU
KALS-1	M1jmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT1PYJMUUN3ME2wMlEyOzl\|IN88US=>	MYXTRW5ITVJ?
RKO	NXfES2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\HbmlEPTB;MD6xNVc3PCEQvF2=	Mn\MV2FPT0WU
OMC-1	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPWTWM2OD1yLkGxO\|k4KM7:TR?=	NHfneZdUSU6JRWK=
BT-549	M1PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS1TWM2OD1yLkGxO\|k6KM7:TR?=	NYPSW4RXW0GQR1XS
NCI-H28	M3rL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTUTWM2OD1yLkGxPFE4KM7:TR?=	M1nKU3NCVkeHUh?=
RXF393	M{W0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljmTWM2OD1yLkGxPVgzKM7:TR?=	NHTIZ4pUSU6JRWK=
COLO-829	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMUKwNFUh\|ryP	MYDTRW5ITVJ?
HMV-II	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jVcGlEPTB;MD6xNlAzKM7:TR?=	M1K1VXNCVkeHUh?=
SW1990	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnGwTWM2OD1yLkGyNVU4KM7:TR?=	NYq0[3hxW0GQR1XS
NCI-H1437	M4Xmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELvbGRKSzVyPUCuNVIyPTdizszN	NHfqUlVUSU6JRWK=
SNB75	NXnWVZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDNTWM2OD1yLkGyNVY6KM7:TR?=	NUS0d5lGW0GQR1XS
EW-3	NEjvWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\2TWM2OD1yLkGyOlYyKM7:TR?=	NIm1[4JUSU6JRWK=
SAS	M4G4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnZTWM2OD1yLkGyOlkh\|ryP	MlLtV2FPT0WU
NCI-H1666	M4XTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPFUVRKSzVyPUCuNVI4PzRizszN	Mn;pV2FPT0WU
A375	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMUK3O\|gh\|ryP	NFLpTWFUSU6JRWK=
CAMA-1	NVr6V5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfiW\|BEUUN3ME2wMlEzQTJ2IN88US=>	NEm1SllUSU6JRWK=
HuP-T4	NUjwVHIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPEb\|Z1UUN3ME2wMlEzQTR\|IN88US=>	MVLTRW5ITVJ?
NCI-H292	M3S5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMUOxNUDPxE1?	NGTzR3dUSU6JRWK=
PC-14	M4\kZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMUOyNVEh\|ryP	MmnHV2FPT0WU
BPH-1	NVXnbHc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMUO0NUDPxE1?	M1zuUnNCVkeHUh?=
GAK	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mom3TWM2OD1yLkGzOVY4KM7:TR?=	MmCzV2FPT0WU
VMRC-RCZ	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV6xWZJPUUN3ME2wMlE{PzZ{IN88US=>	Mn\uV2FPT0WU
SK-MEL-24	NXXlWZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3DfWVKSzVyPUCuNVM5PyEQvF2=	NET4XmFUSU6JRWK=
LB831-BLC	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7sRYhYUUN3ME2wMlE{QDh\|IN88US=>	NYXqcI1HW0GQR1XS
NCI-H2452	NVPOUW1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljWTWM2OD1yLkGzPVU3KM7:TR?=	M2LrcXNCVkeHUh?=
RT-112	NGPLUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17W[WlEPTB;MD6xOFA{PSEQvF2=	MnHWV2FPT0WU
GP5d	NH\QUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMUSxNFQh\|ryP	MYPTRW5ITVJ?
LC-2-ad	MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Oxc2lEPTB;MD6xOFEzOSEQvF2=	M1;2UHNCVkeHUh?=
MPP-89	M3jUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ftdGlEPTB;MD6xOFEzPSEQvF2=	MkPpV2FPT0WU
NUGC-3	NGTYeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULvOXdRUUN3ME2wMlE1PDd6IN88US=>	Mo\EV2FPT0WU
GI-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3OTWM2OD1yLkG0OVU5KM7:TR?=	NVewOWM6W0GQR1XS
HCC1419	NF[xeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\wSGlEPTB;MD6xOFU4PiEQvF2=	NIfVTJBUSU6JRWK=
SW1573	M1TDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMUS3OVgh\|ryP	MUnTRW5ITVJ?
NCI-H2347	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLqbHJKSzVyPUCuNVQ5OzlizszN	NXvuU2pWW0GQR1XS
Mewo	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMUS4PFkh\|ryP	MYXTRW5ITVJ?
639-V	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XRTmlEPTB;MD6xOVAyOyEQvF2=	NXe5S49xW0GQR1XS
AsPC-1	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMUWyNlUh\|ryP	MoXCV2FPT0WU
NCI-H1648	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;CNXNKUUN3ME2wMlE2OjN{IN88US=>	NVj2PGNzW0GQR1XS
786-0	NX7Uc5ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMUWzPFEh\|ryP	NYTTO\|FEW0GQR1XS
ETK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2njUGlEPTB;MD6xOVkh\|ryP	MomyV2FPT0WU
BxPC-3	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrCNllKSzVyPUCuNVU6PjZizszN	MVrTRW5ITVJ?
CAL-62	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zGRmlEPTB;MD6xOlE3QSEQvF2=	NFS0SnRUSU6JRWK=
HCC1937	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMU[yO\|Uh\|ryP	Mn3aV2FPT0WU
NCI-H1299	NF\TfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMU[yPFUh\|ryP	NEfy[otUSU6JRWK=
SW1088	NGDFSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDPRYlKSzVyPUCuNVY1OTNizszN	NULMbpJsW0GQR1XS
FTC-133	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;xTWM2OD1yLkG2OVQh\|ryP	NHS4eWRUSU6JRWK=
OC-314	M1;uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDlOWVKSzVyPUCuNVY3QSEQvF2=	NH7hcFdUSU6JRWK=
SCC-9	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLVTWM2OD1yLkG2O\|E3KM7:TR?=	MU\TRW5ITVJ?
HT-1376	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMU[5N\|Yh\|ryP	MoP2V2FPT0WU
U-2-OS	M4XXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPSUFc3UUN3ME2wMlE4OTd\|IN88US=>	NXm1dVhZW0GQR1XS
COLO-824	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfmVWhKSzVyPUCuNVczQTRizszN	M3KyZ3NCVkeHUh?=
BB30-HNC	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorlTWM2OD1yLkG3N\|Mh\|ryP	NIPYV\|RUSU6JRWK=
NCI-H2087	NIPEXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvsXIFKSzVyPUCuNVc{PjhizszN	NYPsbVVUW0GQR1XS
NCI-H2170	NYqzdo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUe1N\|Yh\|ryP	NX\hcFB1W0GQR1XS
SK-OV-3	M4PBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfye5RKSzVyPUCuNVc2PzFizszN	NFjBTI1USU6JRWK=
MZ7-mel	NUGwTY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnmV3dvUUN3ME2wMlE4PjR7IN88US=>	M3H1XXNCVkeHUh?=
NCI-H650	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf2eWV4UUN3ME2wMlE4Pjh{IN88US=>	MXvTRW5ITVJ?
KOSC-2	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHriUYhKSzVyPUCuNVc4OzRizszN	MWfTRW5ITVJ?
SCC-4	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn0XWd5UUN3ME2wMlE4Pzd5IN88US=>	NHL1bWFUSU6JRWK=
MDA-MB-157	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPWVZlKSzVyPUCuNVgxQDJizszN	M2TWSnNCVkeHUh?=
KYSE-520	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUiyJO69VQ>?	NIGzepFUSU6JRWK=
LK-2	NYPRVYloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nsUmlEPTB;MD6xPFMxOyEQvF2=	MkTHV2FPT0WU
KNS-81-FD	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPXO41yUUN3ME2wMlE5Ozl2IN88US=>	MWfTRW5ITVJ?
IGROV-1	NGDMS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3L3fWlEPTB;MD6xPFQ1OyEQvF2=	MWjTRW5ITVJ?
DEL	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfSRmZqUUN3ME2wMlE5PDVizszN	NXvFWoZkW0GQR1XS
NCI-H1395	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS4c3RtUUN3ME2wMlE5Pjh{IN88US=>	MVfTRW5ITVJ?
JEG-3	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnjTWM2OD1yLkG4O\|A2KM7:TR?=	MVjTRW5ITVJ?
BCPAP	NIfscVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTVTWM2OD1yLkG4PFczKM7:TR?=	NI\lbmVUSU6JRWK=
CAL-27	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMUmwNlIh\|ryP	MnOyV2FPT0WU
RD	NIL6TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMUmxNVMh\|ryP	MWrTRW5ITVJ?
RVH-421	NWHmUpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPMb3NKSzVyPUCuNVkyOTZizszN	NFOwPW9USU6JRWK=
Capan-2	NIXVV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH1S4x4UUN3ME2wMlE6OjV4IN88US=>	MWDTRW5ITVJ?
COLO-680N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPZTWM2OD1yLkG5N\|Y1KM7:TR?=	MWDTRW5ITVJ?
NCI-H1650	NX3IUZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7VTWM2OD1yLkKwNFU4KM7:TR?=	NE\kN4JUSU6JRWK=
SBC-5	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMkCxNVgh\|ryP	NEHaO5FUSU6JRWK=
U031	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMkC1OFch\|ryP	MkfOV2FPT0WU
S-117	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:xOYRKSzVyPUCuNlA2PjRizszN	NWfiOFFJW0GQR1XS
DoTc2-4510	NEmwNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPTTWM2OD1yLkKwO\|Y6KM7:TR?=	M3POc3NCVkeHUh?=
AM-38	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HWeGlEPTB;MD6yNFg1QCEQvF2=	MVvTRW5ITVJ?
A172	NUjR[pE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjqWmpKSzVyPUCuNlExOjJizszN	MXLTRW5ITVJ?
HPAF-II	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrDXlJKSzVyPUCuNlEzPjRizszN	MVXTRW5ITVJ?
769-P	NVi2[YM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHNS5JKSzVyPUCuNlEzQCEQvF2=	MYjTRW5ITVJ?
MFE-280	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moq2TWM2OD1yLkKxNlk5KM7:TR?=	MkPlV2FPT0WU
TE-9	NEPoXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMkG3PFYh\|ryP	M1zO[3NCVkeHUh?=
C2BBe1	M3LSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W1fWlEPTB;MD6yNlE6KM7:TR?=	NXruWZVFW0GQR1XS
EoL-1-cell	M1\lTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rjWmlEPTB;MD6yNlIxOyEQvF2=	M1zme3NCVkeHUh?=
G-361	NVXuU\|cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLVe\|BKSzVyPUCuNlI3QDJizszN	NVrJboo4W0GQR1XS
KYSE-270	NEn6[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS0XlJtUUN3ME2wMlI{ODh2IN88US=>	MYrTRW5ITVJ?
TK10	NX3DZZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMkOxNVch\|ryP	NF;6fFRUSU6JRWK=
ML-2	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXzSVdHUUN3ME2wMlI{OTF7IN88US=>	M1zr[nNCVkeHUh?=
MHH-ES-1	NFzsPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMkO2PFEh\|ryP	Mn\qV2FPT0WU
BHY	NUPWb2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPDWGR7UUN3ME2wMlI{PjlzIN88US=>	NHrMTXVUSU6JRWK=
LS-513	M4nPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4W2WGlEPTB;MD6yN\|k3OSEQvF2=	NXL3T4c6W0GQR1XS
COLO-678	NIf4eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMkSwOFQh\|ryP	NH;1eJFUSU6JRWK=
NCI-H747	NVjHcmtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrMTWM2OD1yLkK0NVY6KM7:TR?=	MYfTRW5ITVJ?
K5	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMkSzPEDPxE1?	M4DrbHNCVkeHUh?=
OS-RC-2	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDqTWM2OD1yLkK0OVA6KM7:TR?=	NX\6bVN4W0GQR1XS
KINGS-1	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PPb2lEPTB;MD6yOFUzQSEQvF2=	MnjjV2FPT0WU
SCC-25	NGLWdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMkS1OlMh\|ryP	M2PPSnNCVkeHUh?=
CAPAN-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jPeWlEPTB;MD6yOFc5OyEQvF2=	MVHTRW5ITVJ?
ESS-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDFeWdtUUN3ME2wMlI1QDB3IN88US=>	MlHPV2FPT0WU
TE-6	NXrDSlQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULpPXZJUUN3ME2wMlI2PzVizszN	Ml7UV2FPT0WU
LB2518-MEL	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTUTWM2OD1yLkK1O\|c4KM7:TR?=	NWTDU2E3W0GQR1XS
COLO-800	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHMTWM2OD1yLkK1PFEzKM7:TR?=	NHL1XWpUSU6JRWK=
LU-134-A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXoTWM2OD1yLkK2NVM3KM7:TR?=	M2[0cXNCVkeHUh?=
NCI-H1155	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS2TWM2OD1yLkK2NVYzKM7:TR?=	NHLlVVFUSU6JRWK=
MFM-223	NVP3elJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPyXFBKSzVyPUCuNlY{PjNizszN	NXjEZpUyW0GQR1XS
HTC-C3	NWjUbZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j3RWlEPTB;MD6yOlUxPiEQvF2=	NYrsZVRvW0GQR1XS
HCT-116	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rCUmlEPTB;MD6yOlU6QSEQvF2=	NHL4fldUSU6JRWK=
Ca-Ski	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{faUGlEPTB;MD6yOlY4QCEQvF2=	M4Cx[nNCVkeHUh?=
SBC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMk[3OFIh\|ryP	Mm\0V2FPT0WU
NB69	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\3TWM2OD1yLkK3NFg4KM7:TR?=	NXzpRoExW0GQR1XS
J82	NYPzfmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMkeyOlUh\|ryP	MWrTRW5ITVJ?
U-118-MG	NX3NPY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPZcYhKSzVyPUCuNlc2PzlizszN	M{HyeXNCVkeHUh?=
NCI-H1355	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMkiwO\|Qh\|ryP	M4PNfHNCVkeHUh?=
NCI-H1048	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnvTWM2OD1yLkK4PVU3KM7:TR?=	NV7IeYFsW0GQR1XS
SW954	NFiyc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXt[I9KSzVyPUCuNlkzOjdizszN	MnmwV2FPT0WU
NMC-G1	NWfobVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMkmyO\|ch\|ryP	NUjpbW1MW0GQR1XS
SW1710	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\JOmlEPTB;MD6yPVQ6PCEQvF2=	MUjTRW5ITVJ?
KY821	M1fRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\BTZUzUUN3ME2wMlI6QDd{IN88US=>	M4rNU3NCVkeHUh?=
HCC38	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwM{CwO\|gh\|ryP	NH23b4tUSU6JRWK=
NCI-SNU-5	NWrWc3hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPnSINKSzVyPUCuN\|A2PCEQvF2=	NUe5cZduW0GQR1XS
ES8	NETVbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M365S2lEPTB;MD6zNFc5PCEQvF2=	MoXJV2FPT0WU
COLO-792	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Kw[mlEPTB;MD6zNVI2OSEQvF2=	MoXXV2FPT0WU
BFTC-905	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXRTWM2OD1yLkOxOVIyKM7:TR?=	NEO2OFhUSU6JRWK=
ChaGo-K-1	M3fydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwM{G3NVUh\|ryP	MYXTRW5ITVJ?
Daoy	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\xb4ZCUUN3ME2wMlMyPzJ\|IN88US=>	MY\TRW5ITVJ?
SJSA-1	M3\uRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2D5WWlEPTB;MD6zNVg1PyEQvF2=	NHuwOoZUSU6JRWK=
KNS-62	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fNTWlEPTB;MD6zNlA5QCEQvF2=	Ml7pV2FPT0WU
CAKI-1	M2rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwM{KxNVEh\|ryP	MWfTRW5ITVJ?
UACC-62	NXuyd\|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HnN2lEPTB;MD6zNlIzPyEQvF2=	NXWyO2p2W0GQR1XS
HuCCT1	M2OwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\ORllKSzVyPUCuN\|IzQDNizszN	NULqT4tlW0GQR1XS
CTB-1	NGHEZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWThXWtzUUN3ME2wMlMzPzV\|IN88US=>	MoXZV2FPT0WU
NTERA-S-cl-D1	M{nKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLxdIFKSzVyPUCuN\|I5OzZizszN	NX;Zb5NuW0GQR1XS
T-24	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP4TWM2OD1yLkOzNVU6KM7:TR?=	M2nzOHNCVkeHUh?=
KYSE-70	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPSfVFbUUN3ME2wMlM{Ojh\|IN88US=>	M2P1[nNCVkeHUh?=
SW626	M4TCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLSO21KSzVyPUCuN\|M2OzJizszN	MV7TRW5ITVJ?
LB996-RCC	NH\IOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHmNJFKSzVyPUCuN\|M3OTlizszN	NV;WUG11W0GQR1XS
DMS-273	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH36TYtKSzVyPUCuN\|M6OTZizszN	NHfiWVlUSU6JRWK=
SW1783	M1m0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1e2OWlEPTB;MD6zN\|k6PyEQvF2=	MVzTRW5ITVJ?
KU812	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlP3TWM2OD1yLkO0NFM5KM7:TR?=	MVzTRW5ITVJ?
HSC-2	NV\XOnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfjTWM2OD1yLkO0NFU{KM7:TR?=	MUHTRW5ITVJ?
A3-KAW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHLTWM2OD1yLkO0NVYzKM7:TR?=	NUjjXFhEW0GQR1XS
COLO-684	M1PzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7ETWM2OD1yLkO0OVAyKM7:TR?=	NVK5[2xbW0GQR1XS
NCI-H2405	NW\qVoZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XrRmlEPTB;MD6zOFY{OSEQvF2=	NGm5XWhUSU6JRWK=
NCI-H2228	NI\yTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\ETWM2OD1yLkO1N\|U4KM7:TR?=	MWHTRW5ITVJ?
NB13	NVHsUlg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwM{[4Nlkh\|ryP	Mor2V2FPT0WU
no-11	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVroXWpMUUN3ME2wMlM3QTVizszN	NICzeoZUSU6JRWK=
DK-MG	NYm0bplKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjWTWM2OD1yLkO3NVg5KM7:TR?=	MWrTRW5ITVJ?
NBsusSR	NHLDTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SyTWlEPTB;MD6zO\|I5PSEQvF2=	M3GybXNCVkeHUh?=
KP-N-YS	NIO1TJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPWVIhmUUN3ME2wMlM4PDZ\|IN88US=>	M{exPHNCVkeHUh?=
CFPAC-1	NGjQPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rxN2lEPTB;MD6zO\|UyQCEQvF2=	MkfEV2FPT0WU
KARPAS-45	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH5cYpKSzVyPUCuN\|c5PjJizszN	MVvTRW5ITVJ?
NCI-H1793	NIrHdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwM{i1NUDPxE1?	NUjaTYsyW0GQR1XS
HCE-T	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnEUI43UUN3ME2wMlM5PjB\|IN88US=>	NX;vNXNJW0GQR1XS
NCI-H520	NEjOW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTrO\|VkUUN3ME2wMlM5PzB\|IN88US=>	MX;TRW5ITVJ?
HCC2157	NVnmZ2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jjemlEPTB;MD6zPFc5OSEQvF2=	MnewV2FPT0WU
EW-18	NXHKOI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwM{i5OFEh\|ryP	Mk\vV2FPT0WU
RO82-W-1	NVPHVJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIO5T3dKSzVyPUCuN\|k3QTlizszN	Mn7yV2FPT0WU
HuP-T3	MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\UTWM2OD1yLkSwNVQ{KM7:TR?=	MnfpV2FPT0WU
PANC-10-05	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNEGxO{DPxE1?	MXTTRW5ITVJ?
NCI-H1703	M3:zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7pVXVKSzVyPUCuOFE1PDZizszN	Mnz5V2FPT0WU
TE-10	M3;CPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwNEG0OFch\|ryP	M4LZfHNCVkeHUh?=
HOS	NEXqSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv6SW5uUUN3ME2wMlQyPjh{IN88US=>	Mom3V2FPT0WU
LN-405	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq5cotKSzVyPUCuOFE3QDdizszN	MXXTRW5ITVJ?
A427	NFHTbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwNEG5PFEh\|ryP	M4j6eHNCVkeHUh?=
CAL-12T	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNEK3PEDPxE1?	M3rTXXNCVkeHUh?=
SW756	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXPXXAyUUN3ME2wMlQ1OTh\|IN88US=>	NGm0OWhUSU6JRWK=
YAPC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3oc4RKSzVyPUCuOFUxQCEQvF2=	MmCzV2FPT0WU
GOTO	NVTDZm1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPQTWM2OD1yLkS1NVYh\|ryP	MkfXV2FPT0WU
C3A	NFTWbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwNEW0N\|ch\|ryP	M37hXHNCVkeHUh?=
UM-UC-3	NFzJ[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPa[Y1KSzVyPUCuOFU1PyEQvF2=	M3vySXNCVkeHUh?=
NCI-H1573	NEDM[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LkO2lEPTB;MD60OVU3QSEQvF2=	MXvTRW5ITVJ?
LS-411N	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwNE[1Nlch\|ryP	NUTQcndGW0GQR1XS
COR-L23	NHfidVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwNE[3OlQh\|ryP	NEHZW\|hUSU6JRWK=
HCE-4	NV7h[Hk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm0TWM2OD1yLkS3OFQ3KM7:TR?=	NVzFeWZmW0GQR1XS
NCI-H2291	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjwR5U4UUN3ME2wMlQ4QDl4IN88US=>	NV7uZXpzW0GQR1XS
A101D	M3n1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPEU4lKSzVyPUCuOFgxPTNizszN	NYXPe5ROW0GQR1XS
HT-3	NH\lWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFiz[2RKSzVyPUCuOFgzOTdizszN	MU\TRW5ITVJ?
HOP-62	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNEm4OlUh\|ryP	NHK0bolUSU6JRWK=
PC-3	NUjj[G95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TrcGlEPTB;MD61NVUxPyEQvF2=	M2n2bnNCVkeHUh?=
CTV-1	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnDTWM2OD1yLkWyOlY6KM7:TR?=	NFnpZXVUSU6JRWK=
PANC-08-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHEWINKSzVyPUCuOVMyPzdizszN	NFLKNIpUSU6JRWK=
CAL-120	M4nhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnGZ2dMUUN3ME2wMlU{Ozl7IN88US=>	MlXmV2FPT0WU
UMC-11	M{\tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnLTWM2OD1yLkW1NlM1KM7:TR?=	NG\keFNUSU6JRWK=
MSTO-211H	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwNUW3OlIh\|ryP	Mlj4V2FPT0WU
NCI-H2126	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rmNGlEPTB;MD61OlgyPSEQvF2=	M{DvfnNCVkeHUh?=
SNU-C2B	NFLxWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rIXWlEPTB;MD61O\|k4PyEQvF2=	Mke5V2FPT0WU
DBTRG-05MG	NYX4OYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TLZmlEPTB;MD61PFA2OyEQvF2=	NXXhXHI5W0GQR1XS
MKN1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwNUi3PFMh\|ryP	MVLTRW5ITVJ?
ES3	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPJXXBKSzVyPUCuOVkyOjRizszN	NIfBZ5JUSU6JRWK=
OVCAR-3	M4m5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2f4[WlEPTB;MD61PVM1OSEQvF2=	MUnTRW5ITVJ?
ACHN	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwNkC1Olkh\|ryP	Ml\qV2FPT0WU
SW872	NVu1[WV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nRNmlEPTB;MD62NFc3OyEQvF2=	NIS4XVBUSU6JRWK=
CP66-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXBcok4UUN3ME2wMlYxQTZ7IN88US=>	NUnJNlJUW0GQR1XS
NCI-H661	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HGUGlEPTB;MD62NVExPCEQvF2=	M{fLbHNCVkeHUh?=
UACC-893	M3;TWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm2PZBKSzVyPUCuOlM3QDFizszN	M2\WeHNCVkeHUh?=
JVM-3	M3TiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPp[XNKSzVyPUCuOlM5ODRizszN	MVfTRW5ITVJ?
SF268	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHoTWM2OD1yLk[0N\|Q6KM7:TR?=	NYLa[IhQW0GQR1XS
OCI-AML2	M3G5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr2b3VKSzVyPUCuOlU{QTdizszN	NFvUOJhUSU6JRWK=
RPMI-8226	M2DCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLzTWM2OD1yLk[2N\|I{KM7:TR?=	M13vbHNCVkeHUh?=
MKN28	NWOwR2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwNk[2NlQh\|ryP	NW\I[G85W0GQR1XS
MDA-MB-453	NEHJZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwNkexPEDPxE1?	NEC3cZBUSU6JRWK=
BV-173	M{DnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwNki2O\|kh\|ryP	MlvpV2FPT0WU
NCI-H358	NYjtOZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwNki3NlYh\|ryP	MnrBV2FPT0WU
NCI-H1651	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDhfYZOUUN3ME2wMlch\|ryP	M{HFUXNCVkeHUh?=
MDA-MB-415	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwN{C4Nlkh\|ryP	NFTwOVBUSU6JRWK=
8305C	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIWwOY5KSzVyPUCuO\|I1QThizszN	MlPFV2FPT0WU
EFM-19	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvtb3M{UUN3ME2wMlc{PjdzIN88US=>	M{W5W3NCVkeHUh?=
RERF-LC-MS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwN{S2NVMh\|ryP	M{fpdHNCVkeHUh?=
A388	M4jScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37JSGlEPTB;MD63OlQ3PyEQvF2=	M1HIN3NCVkeHUh?=
GI-ME-N	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LMTGlEPTB;MD63O\|I{PSEQvF2=	M2jJTXNCVkeHUh?=
IGR-1	NELKR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPRUWlMUUN3ME2wMlc6ODR\|IN88US=>	NGfodYNUSU6JRWK=
LNCaP-Clone-FGC	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPrTWM2OD1yLkiwNFA1KM7:TR?=	NH;ZPW5USU6JRWK=
SK-MEL-3	NHqxOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SwXWlEPTB;MD64NVUxQCEQvF2=	NYGzZnFOW0GQR1XS
UACC-257	NULwZ3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln2TWM2OD1yLkiyNlMyKM7:TR?=	NYnz[YFCW0GQR1XS
OE33	NHTPVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\zV2lEPTB;MD64OVExOSEQvF2=	NG\xWJhUSU6JRWK=
QIMR-WIL	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHxOmFKSzVyPUCuPFUyPDFizszN	NHn3WlJUSU6JRWK=
NCI-H2009	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvKTWM2OD1yLki1N\|EyKM7:TR?=	MXHTRW5ITVJ?
NCI-H522	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\LTWM2OD1yLki3O\|g{KM7:TR?=	MmTkV2FPT0WU
Saos-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwOEe4O\|Eh\|ryP	MUDTRW5ITVJ?
NB17	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV34OnJGUUN3ME2wMlg5ODJ3IN88US=>	NFP2fJRUSU6JRWK=
D-392MG	M2[wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXQSWtiUUN3ME2wMlg6OzV4IN88US=>	MkLVV2FPT0WU
SHP-77	NVTVd3AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzoR452UUN3ME2wMlkxPDh3IN88US=>	MnPZV2FPT0WU
SK-MEL-30	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;sXGlEPTB;MD65NVE5PSEQvF2=	M3q0fHNCVkeHUh?=
GCIY	NXHjUZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwOUG4OFMh\|ryP	MlXMV2FPT0WU
HCC70	NIjqdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\YSGlEPTB;MD65NlA2QSEQvF2=	MkfIV2FPT0WU
LU-65	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;BTWM2OD1yLkmyOVkyKM7:TR?=	MXrTRW5ITVJ?
NCI-H1563	NWnDOIltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwOUS4OlUh\|ryP	NFPlUm5USU6JRWK=
KURAMOCHI	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LpcmlEPTB;MD65OVE6OiEQvF2=	MYrTRW5ITVJ?
PA-1	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvhTWM2OD1yLkm1OFI1KM7:TR?=	MonsV2FPT0WU
NOS-1	M1rPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwOUe0PFkh\|ryP	MoPUV2FPT0WU
NCI-H69	NV7JTVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv5ZmxKSzVyPUCuPVc3OzRizszN	NX7nNnRbW0GQR1XS
KYSE-450	NVvvd3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XXOWlEPTB;MD65PFYzPiEQvF2=	M3K0NnNCVkeHUh?=
8505C	NF;ueJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwOUm5PFIh\|ryP	M2fRfnNCVkeHUh?=
TGBC24TKB	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDITWM2OD1zLkCwNFg1KM7:TR?=	M{PHdnNCVkeHUh?=
PFSK-1	NVPz[ZhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDLWpdKSzVyPUGuNFE1OjhizszN	Ml[xV2FPT0WU
EKVX	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH5TVVKSzVyPUGuNFMyOjFizszN	NELzdZNUSU6JRWK=
RCM-1	M2jENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLyZWZKSzVyPUGuNFU2ODdizszN	M2[5Z3NCVkeHUh?=
SW900	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:yUm11UUN3ME2xMlA4QDNizszN	NYfsZXRwW0GQR1XS
D-542MG	M2rSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrOW5VKSzVyPUGuNFc5PTVizszN	MXHTRW5ITVJ?
SK-PN-DW	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfSTWM2OD1zLkGwNFU3KM7:TR?=	NIrPWGJUSU6JRWK=
NCI-H727	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXhVoo1UUN3ME2xMlExOTV2IN88US=>	NWHsU2o5W0GQR1XS
SW837	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTFwMUC5OVQh\|ryP	M3i1ZXNCVkeHUh?=
BT-20	NV6w[I5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGL3Oo5KSzVyPUGuNVEzODRizszN	M2DMUHNCVkeHUh?=
RH-18	M{LudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\DcWk3UUN3ME2xMlE{OTB\|IN88US=>	Mm\QV2FPT0WU
TE-12	NWjkfWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPkTWM2OD1zLkGzN\|M{KM7:TR?=	MXvTRW5ITVJ?
NB10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDkVYJEUUN3ME2xMlE{OzR2IN88US=>	MWHTRW5ITVJ?
AU565	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHzRXo4UUN3ME2xMlE2QTd\|IN88US=>	M3\GRnNCVkeHUh?=
OAW-42	NFr4[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDyTWM2OD1zLkG4N\|A3KM7:TR?=	Ml7FV2FPT0WU
DJM-1	NUfp[WhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFwMUm4PFEh\|ryP	NHnjT5dUSU6JRWK=
HH	NHGyXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HYUWlEPTB;MT6yN\|g{OSEQvF2=	MmjIV2FPT0WU
LAMA-84	M{TVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;ETWM2OD1zLkK3N\|k1KM7:TR?=	M3TaRXNCVkeHUh?=
KNS-42	NUHudJFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvYTWM2OD1zLkOwNlk3KM7:TR?=	NIjXdnZUSU6JRWK=
NCI-H2052	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLRd5JKSzVyPUGuN\|A2ODdizszN	NUjaeW45W0GQR1XS
MLMA	NVywW\|Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFwM{K0NFch\|ryP	MkjkV2FPT0WU
NB12	M1;EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPCTWM2OD1zLkO1OlM3KM7:TR?=	NHrIcmdUSU6JRWK=
NCI-H1838	M1nMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwM{[zNFYh\|ryP	NHj1W5pUSU6JRWK=
NCI-H526	NUjoTWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTFwM{e4OVMh\|ryP	MkTyV2FPT0WU
LS-123	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwM{mwPVQh\|ryP	NIrwXZRUSU6JRWK=
HDLM-2	NXPZRlVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M361e2lEPTB;MT6zPVI4OSEQvF2=	NXvlWGJ6W0GQR1XS
MC-IXC	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGC1fJdKSzVyPUGuOFI{PzFizszN	M1u4PHNCVkeHUh?=
HCT-15	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;LVHNKSzVyPUGuOFMxPjhizszN	NWnhdIZmW0GQR1XS
NCI-H596	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTFwNEWwOlEh\|ryP	NHnKVnJUSU6JRWK=
ZR-75-30	NYnMflc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrRVWdKSzVyPUGuOFcxQDJizszN	MYLTRW5ITVJ?
A704	NFLhXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Tv[GlEPTB;MT62OlU3OyEQvF2=	M3;ubnNCVkeHUh?=
OVCAR-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYryS4FjUUN3ME2xMlY6PjB5IN88US=>	M1O0d3NCVkeHUh?=
SW1417	NX\XT2Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j0SWlEPTB;MT63Nlg1QSEQvF2=	NV;h[3E4W0GQR1XS
CAS-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXqWWhrUUN3ME2xMlc{QTN4IN88US=>	MVzTRW5ITVJ?
IST-SL1	NYPSPY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;PXmlEPTB;MT63PVc2QSEQvF2=	M3fPfHNCVkeHUh?=
A253	NYf4RXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3ZTWM2OD1zLkiyNlM6KM7:TR?=	NWjyVY52W0GQR1XS
EW-16	M3LON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTFwOEK4O\|Uh\|ryP	MX\TRW5ITVJ?
SK-NEP-1	M1LLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjoe485UUN3ME2xMlg3QTh6IN88US=>	NVv0cYhsW0GQR1XS
NCI-H226	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLnTWM2OD1zLki5N\|U6KM7:TR?=	MX;TRW5ITVJ?
HOP-92	NHHPU\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3juWGlEPTB;MT65OlA6QSEQvF2=	NVvjcGFlW0GQR1XS
NCI-H441	NHfUdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nPSGlEPTB;Mj6wNlM{PyEQvF2=	M2\MS3NCVkeHUh?=
LU-139	M4\xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrm[2FKSzVyPUKuNFMyOTRizszN	Mm\aV2FPT0WU
SJRH30	NYjJWmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTJwMESyOVMh\|ryP	NUXXdGFLW0GQR1XS
MG-63	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TYdGlEPTB;Mj6xOFEyOSEQvF2=	MVPTRW5ITVJ?
NH-12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfSTWM2OD1{LkG1NFA3KM7:TR?=	NG\qUnJUSU6JRWK=
NB7	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vjb2lEPTB;Mj6xPVY4OyEQvF2=	M2DPb3NCVkeHUh?=
LB771-HNC	NFrISoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iwXmlEPTB;Mj6yNFU6PSEQvF2=	NVO1d4ZkW0GQR1XS
HCC1569	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HTO2lEPTB;Mj6yOFU5OyEQvF2=	M1n3eHNCVkeHUh?=
D-283MED	NYPUbWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJwMkS3PFIh\|ryP	NV63PYZ1W0GQR1XS
J-RT3-T3-5	NGr3d2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlz3TWM2OD1{LkK1N\|UyKM7:TR?=	Mlv1V2FPT0WU
ATN-1	NXS2bFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILTWldKSzVyPUKuN\|MxQDJizszN	MoPiV2FPT0WU
HCC1954	M3XFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmSyTWM2OD1{LkO0OFA5KM7:TR?=	MXPTRW5ITVJ?
SCC-15	NXrZXpd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITUd4ZKSzVyPUKuN\|k{OTJizszN	NWrZR4hMW0GQR1XS
COLO-668	NWjiOXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfoNmV2UUN3ME2yMlQ{OiEQvF2=	MlvEV2FPT0WU
LB373-MEL-D	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3wR5FDUUN3ME2yMlU1Pjd5IN88US=>	MXHTRW5ITVJ?
no-10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;xcFBKSzVyPUKuOVQ6PDdizszN	NWT0XGJ6W0GQR1XS
HT-1197	NUC4botJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPVRYJKSzVyPUKuOlMyQDhizszN	M3mxR3NCVkeHUh?=
DU-145	M3W5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\tTWM2OD1{Lke5NVYzKM7:TR?=	M2e3NXNCVkeHUh?=
SK-N-AS	NWK0U3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\4TWM2OD1{Lki0OlkzKM7:TR?=	NIrKRYdUSU6JRWK=
MOLT-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljITWM2OD1{Lki1N\|IzKM7:TR?=	NG\lU3BUSU6JRWK=
EW-22	M{LHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPNclhKSzVyPUKuPVI5PDFizszN	MUjTRW5ITVJ?
DB	NYXGPHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHKTWM2OD1{Lkm3O\|U6KM7:TR?=	MmrxV2FPT0WU
HL-60	NV2wOXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jC[mlEPTB;Mz6wOFM4PiEQvF2=	MYrTRW5ITVJ?
SK-N-DZ	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHDR3dDUUN3ME2zMlA2ODd3IN88US=>	M17sc3NCVkeHUh?=
NY	NGj6UpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f4RmlEPTB;Mz6wPFU1OiEQvF2=	NXn2NGVrW0GQR1XS
T47D	M1jqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\BemlEPTB;Mz6xNFU2QCEQvF2=	M3rIPXNCVkeHUh?=
NCI-H2029	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nqS2lEPTB;Mz6yNlQ4PyEQvF2=	MnvDV2FPT0WU
KARPAS-299	M4TtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfLTWM2OD1\|LkK2NFI4KM7:TR?=	NXPicGZ5W0GQR1XS
KM-H2	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\ROZlQUUN3ME2zMlMxPjhizszN	NGjaRpJUSU6JRWK=
CHP-134	NEXTVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITF[pFKSzVyPUOuOFc{QSEQvF2=	MmTDV2FPT0WU
22RV1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\yTWM2OD1\|LkS5NVY5KM7:TR?=	M2HITnNCVkeHUh?=
NB5	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnPWoE{UUN3ME2zMlUxPjh7IN88US=>	NICwPZdUSU6JRWK=
CW-2	MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jwemlEPTB;Mz61OVMyPCEQvF2=	NIjYV45USU6JRWK=
EFO-21	NVXBbWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4i3[WlEPTB;Mz61Olk1KM7:TR?=	NXX0PXd2W0GQR1XS
HuH-7	M{LleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLwNGFbUUN3ME2zMlU5PDF2IN88US=>	NX30bXg{W0GQR1XS
ALL-PO	M13BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7UZ2dwUUN3ME2zMlYzOzN3IN88US=>	M37HcXNCVkeHUh?=
EM-2	NW\m[4drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nES2lEPTB;Mz62PVAyOSEQvF2=	M4PURXNCVkeHUh?=
KLE	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4L0bWlEPTB;Mz63N\|AzQSEQvF2=	NWPsV\|hbW0GQR1XS
NEC8	NITyelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTNwOUG4NFgh\|ryP	MVXTRW5ITVJ?
KP-N-YN	NWLhSJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO5dHlkUUN3ME2zMlk{PDd4IN88US=>	MkfIV2FPT0WU
SK-MEL-1	M2fOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\QVoVjUUN3ME20MlA{PTF6IN88US=>	M3fKW3NCVkeHUh?=
CAL-54	NIH2dWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTRwMEW5NUDPxE1?	M1\NUnNCVkeHUh?=
MS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULqT3ljUUN3ME20MlE3OTV3IN88US=>	M1\pRnNCVkeHUh?=
NCI-H209	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzKUWJiUUN3ME20MlI6QTl7IN88US=>	MVjTRW5ITVJ?
NOMO-1	NXLP[5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTRwM{KxN\|Eh\|ryP	MnrxV2FPT0WU
RPMI-2650	NG\SNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3roZWlEPTB;ND6zOlMzPyEQvF2=	MlK2V2FPT0WU
NCI-H810	NUi5TGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTRwM{m3N\|Yh\|ryP	Mn;SV2FPT0WU
Ca9-22	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PyPWlEPTB;ND60OVY6OSEQvF2=	NXj3U\|RHW0GQR1XS
ES4	NGTMZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvhNppKSzVyPUSuOFcxQTVizszN	MoW1V2FPT0WU
ES6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTRwNEm2OVch\|ryP	MoPMV2FPT0WU
DMS-114	NWTZOGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHiz[lBKSzVyPUSuOVQ3QTFizszN	NGi2XG1USU6JRWK=
ONS-76	NG[1UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LzTGlEPTB;ND61O\|k2KM7:TR?=	MofwV2FPT0WU
K-562	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfsUFhrUUN3ME20Mlc{QDF2IN88US=>	NEC5b5pUSU6JRWK=
MHH-NB-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmSyTWM2OD12Lke1OFYyKM7:TR?=	NInoV2ZUSU6JRWK=
Calu-3	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLqT\|E{UUN3ME20Mlc5PTR6IN88US=>	MkPxV2FPT0WU
HT55	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rWcWlEPTB;ND64OFU1PSEQvF2=	MWPTRW5ITVJ?
SK-N-FI	NIe0V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLlTWM2OD12Lki1NFA6KM7:TR?=	M{\rSnNCVkeHUh?=
ES1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTLXlhwUUN3ME20Mlg3ODV5IN88US=>	MXLTRW5ITVJ?
SF126	NYTRVXBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmyT4dKSzVyPUSuPVMyQDRizszN	MVfTRW5ITVJ?
ES5	M{fG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrnTWM2OD13LkGyOFI4KM7:TR?=	M4jQZ3NCVkeHUh?=
LoVo	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO1TWM2OD13LkG1PFcyKM7:TR?=	NX\GcJk1W0GQR1XS
SNU-387	NW\Ne4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvDXJhKSzVyPUWuN\|I{OzlizszN	M4HFSnNCVkeHUh?=
C8166	NIi4V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTVwM{[zN\|kh\|ryP	MmjzV2FPT0WU
LS-1034	NHu5XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fYXGlEPTB;NT60NlMxPyEQvF2=	MkHmV2FPT0WU
GR-ST	NF3DS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\SXJlnUUN3ME21MlUzOjBzIN88US=>	MV\TRW5ITVJ?
NCI-H1092	NVf0PXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHmTWM2OD13LkeyPFQ{KM7:TR?=	MnPLV2FPT0WU
647-V	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTVwN{S3NFYh\|ryP	MVXTRW5ITVJ?
EW-13	M2rQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoewTWM2OD13Lke2OlI4KM7:TR?=	MljlV2FPT0WU
KGN	NUXOdpljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX34UJdEUUN3ME22MlA6QTJzIN88US=>	NWnNTWFQW0GQR1XS
D-423MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTZwNECyPFQh\|ryP	M2LxT3NCVkeHUh?=
ECC10	M1rze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTdwMUCxNFEh\|ryP	M1XsN3NCVkeHUh?=
TE-5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DPbWlEPTB;Nz60NVI6QCEQvF2=	M4TLcHNCVkeHUh?=
P12-ICHIKAWA	NV;ucW9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jCNWlEPTB;Nz60OVUzOyEQvF2=	MVLTRW5ITVJ?
NCI-H82	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjOTWM2OD15LkS1O\|AyKM7:TR?=	NWi1Z\|JTW0GQR1XS
NCI-H1993	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7yUWR1UUN3ME23Mlg{ODZ\|IN88US=>	NV;od2hVW0GQR1XS
RH-1	NW[3eFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjLdZVpUUN3ME23Mlg2OjR2IN88US=>	MkW5V2FPT0WU
SW948	NFq2fm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\Q[lhvUUN3ME23Mlk3ODR7IN88US=>	NX;tTlNYW0GQR1XS
CAL-33	NYPRN2JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTdwOUm5N\|gh\|ryP	NFjMNllUSU6JRWK=
U-266	M{\Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzETWM2OD16LkG1O\|c4KM7:TR?=	MUfTRW5ITVJ?
CAL-72	M{\1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvpTWM2OD16LkKwN\|Ih\|ryP	NXTvT25xW0GQR1XS
SNU-423	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LocGlEPTB;OT6zOlY3PiEQvF2=	MW\TRW5ITVJ?
KG-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTlwNUi0OVYh\|ryP	M17wSnNCVkeHUh?=
HCC1395	NULFR4syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfse4V7UUN3ME25MlkzOzV{IN88US=>	NWO0PFNKW0GQR1XS
BE-13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUj2eHJLUUN3ME2xNE45QDl{IN88US=>	M3\lO3NCVkeHUh?=
MKN7	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[4cmlEPTB;MUCuPVc3PSEQvF2=	M2XIZXNCVkeHUh?=
697	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr1TWM2OD1zMT6xOFczKM7:TR?=	M2LvTHNCVkeHUh?=
LU-135	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL2dXdKSzVyPUGxMlI{ODdizszN	MnrDV2FPT0WU
ES7	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;DO2pKSzVyPUGxMlM{OTNizszN	NXfBSW9wW0GQR1XS
SK-HEP-1	NYjBXIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfjb5RKSzVyPUGxMlc3PDZizszN	NHz6So5USU6JRWK=
BEN	NHT0SFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFzLki1NUDPxE1?	NYGycVlSW0GQR1XS
NCI-H1770	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS2TWM2OD1zMj6xNlYh\|ryP	M4DOUXNCVkeHUh?=
SW13	NV3iZ5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rYfmlEPTB;MUKuNVU1OSEQvF2=	NWW4SGZCW0GQR1XS
MZ1-PC	M1K1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzrO4pKSzVyPUGyMlU1PTJizszN	MVvTRW5ITVJ?
Mo-T	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HwUWlEPTB;MUKuO\|QzOSEQvF2=	MW\TRW5ITVJ?
HLE	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXwTWM2OD1zMj64NlE2KM7:TR?=	MV;TRW5ITVJ?
RCC10RGB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTF\|Lk[3NUDPxE1?	M2C1dnNCVkeHUh?=
COLO-320-HSR	NWHzR5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PoemlEPTB;MUOuO\|M5OSEQvF2=	Moj1V2FPT0WU
BHT-101	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonoTWM2OD1zMz64N\|Q2KM7:TR?=	M2L5ZnNCVkeHUh?=
OCUB-M	NID0XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF2LkG2NFIh\|ryP	NFG1VHZUSU6JRWK=
MEG-01	NWX5VotCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLZTWM2OD1zND6zO\|A5KM7:TR?=	NXfaS\|kzW0GQR1XS
RS4-11	M{PBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\5b45KSzVyPUG0Mlc1OiEQvF2=	M4jwSXNCVkeHUh?=
MN-60	NHyyXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzxb3JKSzVyPUG0Mlc5QTRizszN	MVzTRW5ITVJ?
NCI-H1304	M33DbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe4UZdKSzVyPUG1MlA1OjVizszN	MkDsV2FPT0WU
Ramos-2G6-4C10	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zYXmlEPTB;MUWuNFU5OSEQvF2=	NWHuVHJmW0GQR1XS
NCI-H2342	NUnmZmVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1niWmlEPTB;MUWuNlA1PCEQvF2=	M{fFbHNCVkeHUh?=
LAN-6	M{HiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnUTWM2OD1zNT60OFE1KM7:TR?=	MVzTRW5ITVJ?
JVM-2	NXH6e5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGq1XndKSzVyPUG1MlU4PDhizszN	M1HwU3NCVkeHUh?=
P30-OHK	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTF4LkC2NVQh\|ryP	MWjTRW5ITVJ?
C-33-A	NFyw[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjRTWM2OD1zNj62NlE1KM7:TR?=	Mo\iV2FPT0WU
RPMI-8866	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{e3SGlEPTB;MU[uPFQ6PiEQvF2=	NV3RToVwW0GQR1XS
NCI-H630	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFSwS2JKSzVyPUG2Mlg2OzdizszN	MXHTRW5ITVJ?
KYSE-140	NU\QeoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInNXotKSzVyPUG3MlIxOjhizszN	MnnLV2FPT0WU
T84	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3yO4lKSzVyPUG4Mlg3QTVizszN	MnPDV2FPT0WU
KU-19-19	NUHRR2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPmTWM2OD1zOD65OlA5KM7:TR?=	NXzUXGs{W0GQR1XS
BALL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTF7LkOzPVkh\|ryP	MVvTRW5ITVJ?
Calu-6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEL5fpNKSzVyPUG5MlQ6OiEQvF2=	MYDTRW5ITVJ?
EGI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTF7LkW5PEDPxE1?	M2TBOXNCVkeHUh?=
MFH-ino	NXW4O2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:yVpBKSzVyPUG5Mlc1PTRizszN	NY\IVnZ4W0GQR1XS
GB-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q5N2lEPTB;MkCuN\|U{PSEQvF2=	NFr1SlNUSU6JRWK=
NCI-H1693	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXNSm0yUUN3ME2yNE43PTB3IN88US=>	NWDsZ4J4W0GQR1XS
SW1116	M1T1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjaV5B4UUN3ME2yNE46OzZ{IN88US=>	NWTBUGNKW0GQR1XS
H-EMC-SS	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnuTWM2OD1{Mj6wOFUh\|ryP	MXLTRW5ITVJ?
D-502MG	M1fVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnTbo5KSzVyPUKyMlgzPjFizszN	NVe2TY5NW0GQR1XS
IA-LM	M1PEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MneyTWM2OD1{Mz6yOFk{KM7:TR?=	NVrTOm5vW0GQR1XS
SW1463	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XHXWlEPTB;MkOuO\|kh\|ryP	MYXTRW5ITVJ?
JAR	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv5UpFpUUN3ME2yOE4{Ojl\|IN88US=>	M4K3VXNCVkeHUh?=
HT	M{\QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJ2LkS3OVMh\|ryP	MX\TRW5ITVJ?
LCLC-103H	NX73VXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\u[nNKSzVyPUK0Mlg1PDlizszN	Ml\uV2FPT0WU
SNU-449	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn4fZhKSzVyPUK0Mlg4PDFizszN	NH33doJUSU6JRWK=
KE-37	NX73O3E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJ3LkC5Nlgh\|ryP	M4C5c3NCVkeHUh?=
NCI-H1623	M{jvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFqx[3pKSzVyPUK3MlE{ODNizszN	M1fT[XNCVkeHUh?=
MOLT-13	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDEZlFKSzVyPUK3MlM2OTZizszN	MYLTRW5ITVJ?
COLO-741	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLu[nFKSzVyPUOxMlM{OzNizszN	NFnHeZBUSU6JRWK=
NB6	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH5fopyUUN3ME2zNk4zQDd4IN88US=>	M2XKVnNCVkeHUh?=
MOLT-16	M1HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFi0cppKSzVyPUOzMlAxPTVizszN	M3f6U3NCVkeHUh?=
IST-MES1	M2rVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zBNmlEPTB;M{SuNFU1OSEQvF2=	NEXGWXVUSU6JRWK=
A4-Fuk	NVPwV3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;IdGlEPTB;M{WuNFY3KM7:TR?=	NXLadmltW0GQR1XS
CAL-85-1	M4LFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmWzTWM2OD1\|NT6yPFE4KM7:TR?=	MVrTRW5ITVJ?
CCRF-CEM	M3fSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO1[3ByUUN3ME2zO{4yPTN4IN88US=>	NHXLO5JUSU6JRWK=
HAL-01	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTZV4RKSzVyPUO4MlQ5QDlizszN	NVjabI5kW0GQR1XS
HEL	NXz0T5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XHeWlEPTB;NEOuN\|QxQSEQvF2=	MkTIV2FPT0WU
EW-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml32TWM2OD12Mz60O\|Y5KM7:TR?=	MoPYV2FPT0WU
MDA-MB-231	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn5TWM2OD12NT6xNVk6KM7:TR?=	MojpV2FPT0WU
ABC-1	M3;DeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH1TWM2OD12Nj64OVM5KM7:TR?=	NU\Jc\|FwW0GQR1XS
NCI-H446	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXNZ4VjUUN3ME20PE42ODV6IN88US=>	NXj3VYg4W0GQR1XS
MHH-PREB-1	M1HKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHqToVKSzVyPUS5MlYxODdizszN	NXzJNo51W0GQR1XS
DOHH-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTR7Lk[2OVYh\|ryP	MYHTRW5ITVJ?
GCT	M3\1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjNTWM2OD12OT62PVc3KM7:TR?=	MWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

体内研究

17-AAG作用于携带3T3-src, B16或CT26移植瘤裸鼠，与Hsp90结合具有高亲和力，IC50为8-35 nM，而作用于正常组织时，IC50为200-600 nM。^[1] 17-AAG按50 mg/kg左右剂量处理，引起AR, HER2, HER3, 和 Akt表达明显降低，降低达50%以上，这种作用存在剂量依赖性，结果导致雄激素依赖型 (CWR22)和非依赖型(CWR22R 和CWRSA6) 前列腺移植瘤生长受抑制，抑制率分别为67%, 80%和 68%。^[2]

激酶实验：^[1]	- 合并 Hsp90结合实验: 纯化的Hsp90蛋白或过量表达HER-2的癌细胞(BT474, N87, SKOV3 和 SKBR3) 裂解物或BT474乳腺癌细胞溶于溶解buffer(20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) ，与不同浓度17-AAG在4^oC下温育30分钟，然后和生物素-GM链接的BioMag链霉亲和素磁珠在4^oC下温育1小时。试管放置于磁架上,除去未结合的上清液。在溶解buffer中清洗三次磁珠，然后在SDS–PAGE 样本缓冲液中在95^oC下加热5分钟。在SDS蛋白凝胶上进行样本分析,使用特点抗体进行Western Blotting。使用Bio-rad Fluor-S 多重图像测量Western Blot条带，计算抑制Hsp90与生物素-GM结合的百分数。测定IC50。
细胞实验：^[1]	- 合并 Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, 和 PBMC Concentrations: 溶于DMSO, 终浓度为10 μM 左右 Incubation Time: 5天 Method: 细胞按每孔2000个接种在96孔板上，终培养体积为100 μL，培养24小时，然后加入浓度不断增高的17-AAG，温育5天。使用 Celltiter 96 AQueous 非放射性细胞增殖检测试剂盒测定存活细胞数。测定IC50。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下注射雄激素依赖性CWR22移植瘤的雄性 nu/nu 无胸腺小鼠，皮下注射雄激素非依赖性的CWR22R和CWRSA6移植瘤的雌性nu/nu 无胸腺小鼠。 Dosages: 50 mg/kg 左右 Administration: 腹膜注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (170.73 mM)
	Water	Insoluble
	Ethanol	'5 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+corn oil	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Tanespimycin (17-AAG) SDF

分子量	585.69
化学式	C₃₁H₄₃N₃O₈
CAS号	75747-14-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	CP127374,NSC-330507, KOS 953

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
回答：
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

选择性强的HSP90抑制剂

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
活性最高的HSP90抑制剂

KW-2478 : HSP90, IC50=3.8 nM.
用于临床的HSP90抑制剂

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
最新的HSP90抑制剂

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

研究领域

产品类型

定制您的化合物库

Tanespimycin (17-AAG)

客户使用Selleck生产的Tanespimycin (17-AAG)发表文献81篇：

产品安全说明书

HSP (HSP90)抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Tanespimycin (17-AAG) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

相关HSP (HSP90)产品